Abingdon Health Management
Management criteria checks 2/4
Abingdon Health's CEO is Chris Henry Yates, appointed in Jul 2015, has a tenure of 9.42 years. total yearly compensation is £323.00K, comprised of 82.7% salary and 17.3% bonuses, including company stock and options. directly owns 2.05% of the company’s shares, worth £611.39K. The average tenure of the management team and the board of directors is 1.8 years and 12.8 years respectively.
Key information
Chris Henry Yates
Chief executive officer
UK£323.0k
Total compensation
CEO salary percentage | 82.7% |
CEO tenure | 9.4yrs |
CEO ownership | 2.0% |
Management average tenure | 1.8yrs |
Board average tenure | 12.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | UK£323k | UK£267k | -UK£1m |
Mar 31 2024 | n/a | n/a | -UK£2m |
Dec 31 2023 | n/a | n/a | -UK£2m |
Sep 30 2023 | n/a | n/a | -UK£3m |
Jun 30 2023 | UK£278k | UK£225k | -UK£3m |
Mar 31 2023 | n/a | n/a | -UK£11m |
Dec 31 2022 | n/a | n/a | -UK£18m |
Sep 30 2022 | n/a | n/a | -UK£20m |
Jun 30 2022 | UK£222k | UK£203k | -UK£21m |
Mar 31 2022 | n/a | n/a | -UK£17m |
Dec 31 2021 | n/a | n/a | -UK£12m |
Sep 30 2021 | n/a | n/a | -UK£10m |
Jun 30 2021 | UK£455k | UK£251k | -UK£7m |
Mar 31 2021 | n/a | n/a | -UK£5m |
Dec 31 2020 | n/a | n/a | -UK£3m |
Sep 30 2020 | n/a | n/a | -UK£3m |
Jun 30 2020 | UK£228k | UK£213k | -UK£3m |
Compensation vs Market: Chris Henry's total compensation ($USD404.66K) is about average for companies of similar size in the UK market ($USD349.06K).
Compensation vs Earnings: Chris Henry's compensation has increased whilst the company is unprofitable.
CEO
Chris Henry Yates (50 yo)
9.4yrs
Tenure
UK£323,000
Compensation
Mr. Chris Henry Francis Yates has been Independent Non-Executive Director of genedrive plc since August 22, 2018. He Co-Founded diagnostics group Abingdon Health (“Abingdon”) in 2008 and he has been the Ch...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 16.9yrs | UK£89.00k | 3.42% £ 1.0m | |
CEO, Company Secretary & Director | 9.4yrs | UK£323.00k | 2.05% £ 611.4k | |
Group Financial Controller | less than a year | no data | no data | |
Chief Operating Officer | 2.8yrs | no data | no data |
1.8yrs
Average Tenure
Experienced Management: ABDX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 16.9yrs | UK£89.00k | 3.42% £ 1.0m | |
CEO, Company Secretary & Director | 12.8yrs | UK£323.00k | 2.05% £ 611.4k | |
Senior Independent Non-Executive Director | 4.2yrs | UK£41.00k | no data | |
Member of Medical & Scientific Advisory Board | no data | no data | no data | |
Member of Medical & Scientific Advisory Board | no data | no data | no data | |
Member of Medical & Scientific Advisory Board | no data | no data | no data | |
Member of Medical & Scientific Advisory Board | no data | no data | no data |
12.8yrs
Average Tenure
62yo
Average Age
Experienced Board: ABDX's board of directors are seasoned and experienced ( 12.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/19 05:16 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abingdon Health Plc is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Emma Ulker | WH Ireland Limited |
Emma Ulker | Zeus Capital Limited |